Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 13;23(18):10624.
doi: 10.3390/ijms231810624.

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression

Jolanta Orzelska-Górka  1 , Joanna Mikulska  1 , Anna Wiszniewska  1 , Grażyna Biała  1
Affiliations
Review

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression

Jolanta Orzelska-Górka et al. Int J Mol Sci. .

Abstract

Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical observations, suggesting that new atypical antipsychotic drugs are effective against negative and cognitive symptoms of schizophrenia, as well as against affective symptoms observed in depression. The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. We have first provided a brief overview of the major neurobiological underpinnings of schizophrenia and depression. We then shortly discuss efficacy, safety and limitations of ongoing pharmacotherapy used in depression and schizophrenia. Mainly, we have focused this review on the therapeutic potential of new atypical antipsychotic drugs-currently existing-to be effective in psychotic, as well as in affective disorders.

Keywords: aripiprazole; asenapine; brexpiprazole; cariprazine; depression; lumateperone; lurasidone; pimavanserin; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Delay J., Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. J. Clin. Exp. Psychopathol. 1955;16:104–111. - PubMed
    1. Grinchii D., Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int. J. Mol. Sci. 2020;21:9532. doi: 10.3390/ijms21249532. - DOI - PMC - PubMed
    1. Grace A.A., Gomes F.V. The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. Schizophr Bull. 2019;45:148–157. doi: 10.1093/schbul/sbx199. - DOI - PMC - PubMed
    1. Kahn R.S., Sommer I.E., Murray R.M., Meyer-Lindenberg A., Weinberger D.R., Cannon T.D., O’Donovan M., Correll C.U., Kane J.M., van Os J., et al. Schizophrenia. Nat. Rev. Dis. Primers. 2015;12:15067. doi: 10.1038/nrdp.2015.67. - DOI - PubMed
    1. Carbon M., Correll C.U. Thinking and acting beyond the positive: The role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19((Suppl. S1)):38–52. doi: 10.1017/S1092852914000601. - DOI - PubMed

MeSH terms

Grants and funding

The review was supported by Statutory Activity of Medical University of Lublin (DS 23/2022).